Brokerages expect SAGE Therapeutics Inc (NASDAQ:SAGE) to post earnings per share of ($3.37) for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for SAGE Therapeutics’ earnings, with estimates ranging from ($3.60) to ($2.98). SAGE Therapeutics reported earnings of ($2.63) per share during the same quarter last year, which indicates a negative year over year growth rate of 28.1%. The company is scheduled to issue its next earnings results on Tuesday, November 5th.

On average, analysts expect that SAGE Therapeutics will report full year earnings of ($13.32) per share for the current financial year, with EPS estimates ranging from ($14.18) to ($11.45). For the next year, analysts forecast that the business will post earnings of ($12.06) per share, with EPS estimates ranging from ($15.77) to ($8.94). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) EPS for the quarter, beating the consensus estimate of ($3.32) by $0.04. The business had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $0.27 million. The firm’s quarterly revenue was down 99.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.36) EPS.

Several research firms have recently weighed in on SAGE. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, July 24th. Oppenheimer reduced their price objective on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. William Blair reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, July 24th. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Wedbush began coverage on SAGE Therapeutics in a research note on Wednesday, May 22nd. They issued an “outperform” rating and a $207.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $200.27.

In related news, Director James M. Frates sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total transaction of $1,284,640.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE lifted its position in SAGE Therapeutics by 6.3% during the 2nd quarter. US Bancorp DE now owns 1,122 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 66 shares in the last quarter. Cornerstone Advisors Inc. lifted its position in SAGE Therapeutics by 28.3% during the 1st quarter. Cornerstone Advisors Inc. now owns 308 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 68 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in SAGE Therapeutics by 4.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 77 shares in the last quarter. Meadow Creek Investment Management LLC lifted its position in SAGE Therapeutics by 4.6% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 1,808 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 80 shares in the last quarter. Finally, Prudential Financial Inc. lifted its position in SAGE Therapeutics by 4.2% during the 2nd quarter. Prudential Financial Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 100 shares in the last quarter.

Shares of NASDAQ SAGE traded up $0.67 during midday trading on Friday, hitting $161.57. The stock had a trading volume of 5,530 shares, compared to its average volume of 360,666. The company has a market capitalization of $7.84 billion, a price-to-earnings ratio of -20.03 and a beta of 2.55. SAGE Therapeutics has a 1-year low of $79.88 and a 1-year high of $193.56. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.03. The company has a fifty day moving average price of $164.49 and a 200 day moving average price of $168.11.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: Mutual Funds

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.